T.ChipukJ
When it comes to overall wellness, the gut plays a starring role
Disclosures: Stephen Congly: Axcella Health, Inc.: Grant/Research Support, AstraZenica: Grant/Research Support, Merck: Grant/Research Support, Ipsen: Grant/Research Support, Bausch Health: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, AstraZeneca: Consultant, GSK: Consultant, Mayur Brahmania: Nothing to Disclose, Conar O'Neil: Gilead Sciences: Speaking and Teaching, Gilead Sciences: Advisor, AbbVie: Speaking and Teaching, ViiV: Advisor, ViiV: Speaking and Teaching, Karen Doucette: Roche: Grant/Research Support, GSK: Grant/Research Support, Altimmune: Grant/Research Support, Mang Ma: Nothing to Disclose, Carla Coffin: Gilead Sciences: Grant/Research Support, Janssen Pharmaceuticals: Grant/Research Support, GSK: Speaking and Teaching, Altimmune Pharmacueticals: Fund paid to the University of Calgary, Riche Pharmaceuticals: Grant/Research Support, GSK: Funds paid to the University of Calgary 1709 VARIATION IN NULEOS(T)IDE ANALOGUE USE IN MEDICARE PART D THROUGHOUT THE UNITED STATES Stephen Congly 1 Conar O'Neil 2 Karen Doucette 2 Mang Ma 2 Mayur Brahmania 1 Carla Coffin 1 , 1 University of Calgary, 2 University of Alberta Background: Treatment for chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) suppresses viral replication and prevents progression to fibrosis and liver cancer
Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic Index
Ophthalmic Rev
We are proposing to base the FY 2024 market basket update used to determine the applicable percentage increase for the IPPS on IHS Global Inc.'s (IGI's) fourth quarter 2022 forecast of the 2018-based IPPS market basket rate-of-increase with historical data through third quarter 2022, which is estimated to be 3.0 percent
